RepliCel Appoints Brooke Hurford as Corporate Secretary and Director, Finance

RepliCel Appoints Brooke Hurford as Corporate Secretary and Director, Finance 
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 07/16/14 --  
RepliCel Life Sciences Inc. (the "Company") (TSX VENTURE: RP)(OTCQB:
REPCF), today announced that it has appointed Brooke Hurford, CA as
Corporate Secretary and Director, Finance.  
Ms. Hurford is a Chartered Accountant and holds a degree in
Psychology and a diploma in Accounting from the University of British
Columbia. Ms. Hurford has spent several years in public practice
specializing in reviews and audits for public companies. She recently
held a role in the treasury department at the Bank of Montreal. 
Pursuant to its Stock Option Plan, the Company granted 30,000 options
to Ms. Hurford. The options vest over a one year period and are
exercisable at $0.66 per share for five years. 
About RepliCel Life Sciences  
RepliCel is a regenerative medicine company focused on developing
autologous cell therapies that address diseases caused by a deficit
of healthy cells required for normal healing and function such as
chronic tendinosis, damaged skin and pattern baldness. The company's
RCT-01 and RCS-01 cell therapies are designed to treat chronic
tendinosis and damaged or aging skin respectively, using fibroblasts
isolated from the sheath of the hair follicle. Another of the
company's pipeline products, RCH-01 for the treatment of pattern
baldness, is manufactured from cells derived from the hair follicle
dermal cup. Shiseido Company, Limited has an exclusive geographic
license for RCH-01 in certain Asian countries including Japan, China
and South Korea. All product candidates are based on RepliCel's
innovative technology which utilizes cells isolated from a patient's
own healthy hair follicles to address specific cellular deficits. For
additional information please visit www.replicel.com.  
On Behalf of the Board   
RepliCel Life Sciences Inc.  
David Hall, President and Chief Executive Officer  
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 
Contacts:
CORPORATE CONTACT:
RepliCel Life Sciences
Tammey George, Director of Communications
604-248-8696
tg@replicel.com
www.replicel.com 
US INVESTOR RELATIONS:
Westwicke Partners, LLC
Robert H. Uhl, Managing Director
858-356-5932
robert.uhl@westwicke.com 
CANADIAN INVESTOR RELATIONS:
Christina Cameron
christina@clcameron.com
 
 
Press spacebar to pause and continue. Press esc to stop.